Key Takeaways Iovance reported a Q4 loss of 18 cents per share on $87M in revenues, topping estimates.IOVA's Amtagvi sales rose 33% to $65M, lifting gross margin to 50% after restructuring.IOVA shares jumped 31% on 50% ORR data in sarcoma and a new study plan.Iovance Biotherapeutics (IOVA) incurred a fourth-quarter 2025 loss of 18 cents per share, narrower than the Zacks Consensus Estimate of a loss of 22 cents. In the year-ago quarter, the company reported a loss per share of 26 cents.Total revenues for th ...

Key Takeaways Iovance's Amtagvi sales jumped 183% in the first nine months of 2025, driving growth.IOVA cut its 2025 revenue guidance and withdrew its EU filing for Amtagvi, hurting shares.Rigel's 2025 sales rose 60% to $232M, led by Tavalisse, with 2026 growth projected.Both Iovance Biotherapeutics (IOVA) and Rigel Pharmaceuticals (RIGL) are small-cap companies focused on the successful commercialization of their marketed products.While Iovance is a cancer biotech concentrated on developing immunotherapies ...

Iovance Biotherapeutics (NasdaqGM:IOVA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Company ParticipantsAndrew Tsai - Managing DirectorBrian Gastman - EVP of Transitional Medicine and ResearchCorleen Roche - CFODan Kirby - Chief Commercial OfficerDavid Dai - DirectorFrederick Vogt - Interim CEO and PresidentIgor Bilinsky - COOReni Benjamin - Managing DirectorSara Pellegrino - SVP of Investor Relations and Corporate CommunicationsNone - Company RepresentativeConference Call ParticipantsAsthika Goonew ...

Iovance Biotherapeutics (NasdaqGM:IOVA) Q4 2025 Earnings call February 24, 2026 08:30 AM ET Speaker9Good day. Thank you for standing by. Welcome to the Iovance Biotherapeutics fourth quarter and full year 2025 financial results and corporate updates conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during this session, you will need to press star one one on your telephone. You will hear ...

~30% Quarterly Revenue Growth Driven by Amtagvi Demand Gross Margin Increased to 50% FY25 Revenue of $264M Achieved Annual Guidance U.S. FDA Fast Track Designation Granted for Lifileucel in Second-Line Advanced Non-Small Cell Lung Cancer SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer ...

Corporate Overview February 2026 © 2026, Iovance Biotherapeutics, Inc. © 2026, Iovance Biotherapeutics, Inc. 1 Forward-Looking Statements Certain matters discussed in this presentation are "forward-looking statements" of Iovance Biotherapeutics, Inc. (hereinafter referred to as the "Company," "we," "us," or "our") within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Without limiting the foregoing, we may, in some cases, use terms such as "predicts," "believes," "potentia ...

Core Viewpoint - Iovance Biotherapeutics, Inc. will host a conference call and live audio webcast on February 24, 2026, to report its fourth quarter and full year 2025 financial results and corporate updates [1]. Company Overview - Iovance Biotherapeutics, Inc. focuses on innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for cancer patients, aiming to be a global leader in this field [3]. - The company is pioneering a transformational approach to cancer treatment by utilizing the human immune system to recognize and destroy diverse cancer cells [3]. - Iovance's TIL platform has shown promising clinical data across multiple solid tumors, and its product Amtagvi is the first FDA-approved T cell therapy for a solid tumor indication [3]. - The company is committed to continuous innovation in cell therapy, including gene-edited cell therapy, to improve the lives of cancer patients [3].

Group 1 - Iovance Biotherapeutics Inc. expects to achieve full-year 2025 revenue guidance of $250 to $300 million in the first full calendar year of Amtagvi sales [1][2] - Amtagvi, the treatment regimen for advanced melanoma, is projected to have peak sales potential of up to $1 billion [1] - The company has $307 million in cash and cash equivalents, which will fund operations through the second quarter of 2027 [2] Group 2 - Lifileucel, an in-development treatment for lung cancer, has a commercial opportunity that could be up to 7 times larger than the current melanoma treatment market [2] - Enrollment and data updates for Lifileucel are expected to be completed this year, with a launch anticipated in the second half of 2027 [2] - Iovance Biotherapeutics specializes in developing and commercializing cell therapies as novel cancer immunotherapy products [2]

Core Thesis - Iovance Biotherapeutics, Inc. (IOVA) is pursuing a high-risk strategy by opting for equity dilution to fund operations rather than selling at a distressed valuation around $2.50 per share, indicating management's confidence in the long-term potential of its Tumor Infiltrating Lymphocyte platform, especially in lung cancer, which could represent a multibillion-dollar opportunity [2][4] Valuation and Market Perception - The stock trades as if it is a failed biotech, with control held by insiders like Wayne Rothbaum, whose cost basis is approximately $9.00, creating a disconnect between market perception and internal expectations [3] - The valuation gap has stalled acquisition activity, as a typical pharmaceutical buyout premium would still result in significant losses for long-term holders, incentivizing insiders to block offers that do not meet their higher internal valuation [4] Operational Insights - Iovance operates with a unique asset, Amtagvi, but faces economic challenges, with gross margins between 24% to 43%, significantly lower than the 80% to 95% margins typical for commercial oncology drugs, making the standalone model cash-intensive [5] - For a potential acquirer, the success of the thesis depends on whether manufacturing scale can improve margins to 70% or higher; if not, Amtagvi may become a source of profitless revenue [6] Comparative Analysis - The bullish thesis on IOVA shares similarities with a previous analysis of Bio-Techne Corporation (TECH), which highlighted strong growth potential; however, IOVA's profile is characterized by higher risk and reward, with acquisition potential and internal conviction as key drivers [7]

Core Insights - Iovance Biotherapeutics Inc. is identified as a promising biotech penny stock, with Barclays raising its price target to $10 from $9 while maintaining an Overweight rating [1] - The company reported a total product revenue of $68 million in Q3 2025, marking a 13% sequential increase, primarily driven by Amtagvi sales of $58 million [2] - Iovance plans to centralize all Amtagvi and clinical manufacturing at its internal facility by early 2026 to enhance capacity and gross margins [3] Financial Performance - Iovance's Q3 2025 product revenue was $68 million, a 13% increase from the previous quarter [2] - The company reaffirmed its full-year 2025 revenue guidance of $250 to $300 million [2] - Management projects peak US sales for Amtagvi in advanced melanoma to exceed $1 billion, supported by over 80 Authorized Treatment Centers across approximately 40 states [2] Strategic Developments - A major operational shift is planned for early 2026, centralizing manufacturing to eliminate reliance on contract manufacturers and maximize capacity [3] - Iovance is pursuing a larger market in non-small cell lung cancer (NSCLC), with interim data from the IOV-LUN-202 trial showing a 26% objective response rate [4] - Enrollment for the IOV-LUN-202 trial is expected to finish in 2026, supporting a potential supplemental BLA and commercial launch in H2 2027 [4] Company Overview - Iovance Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing cell therapies for metastatic melanoma and other solid tumors in the US [5]